Figures S1-S4, Tables S1-S2 from An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody–Drug Conjugate for the Treatment of Hormone Receptor–Positive Breast Cancer

Bhakta, Sunil; Crocker, Lisa M.; Chen, Yvonne; Hazen, Meredith; Schutten, Melissa M.; Li, Dongwei; Kuijl, Coenraad; Ohri, Rachana; Zhong, Fiona; Poon, Kirsten A.; Go, Mary Ann T.; Cheng, Eric; Piskol, Robert; Firestein, Ron; Fourie-O'Donohue, Aimee; Kozak, Katherine R.; Raab, Helga; Hongo, Jo-Anne; Sampath, Deepak; Dennis, Mark S.; Scheller, Richard H.; Polakis, Paul; Junutula, Jagath R.

doi:10.1158/1535-7163.22505118.v1

Figures S1-S4, Tables S1-S2 from An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody–Drug Conjugate for the Treatment of Hormone Receptor–Positive Breast Cancer

journal contribution

posted on 2023-04-03, 15:05 authored by Sunil Bhakta, Lisa M. Crocker, Yvonne Chen, Meredith Hazen, Melissa M. Schutten, Dongwei Li, Coenraad Kuijl, Rachana Ohri, Fiona Zhong, Kirsten A. Poon, Mary Ann T. Go, Eric Cheng, Robert Piskol, Ron Firestein, Aimee Fourie-O'Donohue, Katherine R. Kozak, Helga Raab, Jo-Anne Hongo, Deepak Sampath, Mark S. Dennis, Richard H. Scheller, Paul Polakis, Jagath R. Junutula

Figure S1. Validation of anti-GFRA1 antibodies (R&D systems and GNE-8H6) for the use of Immunohistochemistry (IHC) analysis; Figure S2. ELISA analyses to test binding specificity of anti-GFRA1 antibodies to GFRA1 (A) and GFRA2 (B) extra cellular domain-Fc fusion proteins; Figure S3. Pharmacokinetics of anti-GFRA1 ADCs in tumor xenograft models; Figure S4. FACS of anti-GFRA1, hu-6D3.v5 (A) and hu-7C9 (B) antibody titration on HEK293-overexpressing human, cynomolgus monkey, rat and mouse GFRA1 cells showing similar binding; Table S1. Affinity characterization of anti-GFRA1 IgG antibodies on Immobilized hu- GFRA1Fc ligand; Table S2. Bioanalytical characterization of anti-GFRA1 ADCs.

History

ARTICLE ABSTRACT

Luminal A (hormone receptor-positive) breast cancer constitutes 70% of total breast cancer patients. In an attempt to develop a targeted therapeutic for this cancer indication, we have identified and characterized Glial cell line–Derived Neurotrophic Factor (GDNF) Family Receptor Alpha 1 (GFRA1) antibody–drug conjugates (ADC) using a cleavable valine-citrulline-MMAE (vcMMAE) linker-payload. RNAseq and IHC analysis confirmed the abundant expression of GFRA1 in luminal A breast cancer tissues, whereas minimal or no expression was observed in most normal tissues. Anti–GFRA-vcMMAE ADC internalized to the lysosomes and exhibited target-dependent killing of GFRA1-expressing cells both in vitro and in vivo. The ADCs using humanized anti-GFRA1 antibodies displayed robust therapeutic activity in clinically relevant cell line–derived (MCF7 and KPL-1) tumor xenograft models. The lead anti-GFRA1 ADC cross-reacts with rodent and cynomolgus monkey GFRA1 antigen and showed optimal pharmacokinetic properties in both species. These properties subsequently enabled a target-dependent toxicity study in rats. Anti-GFRA1 ADC is well tolerated in rats, as seen with other vcMMAE linker–payload based ADCs. Overall, these data suggest that anti–GFRA1-vcMMAE ADC may provide a targeted therapeutic opportunity for luminal A breast cancer patients. Mol Cancer Ther; 17(3); 638–49. ©2017 AACR.